Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

June 20, 2018

Study Completion Date

June 20, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

NI-0101

Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4

OTHER

Placebo

Placebo

Trial Locations (19)

1612

"University Multiprofile Hospital for Active TreatmenT St. Ivan Rilski", Sofia

3529

CRU Hungary Ltd, Miskolc

4000

"Multi-profile Hospital for Active Treatment Trimontsium", Plovdiv

4001

"University Multiprofile Hospital for Active Treatment Kaspela", Plovdiv

9705

Multiprofile Hospital for Active Treatment - Shumen AD, Shumen

11000

Institute of Rheumatology, Belgrade

21112

"Special Hospital for Rheumatic Diseases Novi Sad", Novi Sad

23000

"General Hospital Djordje Joanovic", Zrenjanin

34000

Clinical Center Kragujevac, Kragujevac

88000

Clinic for internal medicine with centre for dialysis, Mostar

0112

ARENSIA Phase I Unit at the Research Institute of Clinical Medicine, Tbilisi

0144

High Technology Medical Center; University clinic, Tbilisi

0159

Emergency Cardiology Center by Acad. G.Chapidze, Tbilisi

Insitute of Clinical Cardiology, Tbilisi

Tbilisi Central Hospital, Tbilisi

0186

Multiprofile Clinic Consilium Medulla, Tbilisi

MD2025

Republican Clinical Hospital, ARENSIA Phase I unit, Chisinau

15-297

Centrum Miriada, Bialystok

20-582

Zespól Poradni Specjalistycznych REUMED, Lublin

All Listed Sponsors
lead

Light Chain Bioscience - Novimmune SA

INDUSTRY